Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.6.0.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Revenues $ 75 $ 134 $ 210 $ 294
Operating expenses:        
Research and development (related party of $206, $252, $445 and $478), net of grant income of $4, $0, $40 and $0) 1,049 704 1,869 1,255
General and administrative (related party of $187, $78, $362 and $78) 2,351 1,684 4,820 3,106
Total operating expenses 3,400 2,388 6,689 4,361
Operating loss (3,325) (2,254) (6,479) (4,067)
Other income (expense):        
Interest expense (related party of $483, $0, $966 and $0) (483) 0 (966) 0
Interest income 12 2 25 4
Royalty income 4 6 16 12
Total other income (expense) (467) 8 (925) 16
Consolidated net loss (3,792) (2,246) (7,404) (4,051)
Net loss attributable to noncontrolling interest 563 0 1,114 0
Net loss attributable to iBio, Inc. (3,229) (2,246) (6,290) (4,051)
Comprehensive loss:        
Consolidated net loss (3,792) (2,246) (7,404) (4,051)
Other comprehensive income (loss) - foreign currency translation adjustments 0 1 0 (8)
Comprehensive loss $ (3,792) $ (2,245) $ (7,404) $ (4,059)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.04) $ (0.03) $ (0.07) $ (0.05)
Weighted-average common shares outstanding - basic and diluted 89,109 77,326 89,109 77,316